Good to have someone level headed on this thread. Obviously more people in ICU is good business case for Uscom-1a. If the drugs reduces the number of critically ill patients, haemodynamics measurement is a bit over kill for most people who have mild/moderate symptoms. Even in ICU, patients already have arterial cannula inserted anyways so it's been hard for UCM to sell the product imo. Unless the standard changes that they monitor haemodynamics for patients with mild/moderate symptoms, it'll difficult sell IMHO.Anyways I have been accumulating below 20c whenever it dipped which I think provides a margin of safety.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.861M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250000 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 42000 | 1 |
View Market Depth
| Last trade - 16.21pm 25/07/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable